Nav: Home

Study finds that more than one-third of patients with metastatic cancer continue to work

December 21, 2015

A new analysis indicates that many patients continue working after being diagnosed with metastatic cancer, but a heavy burden of symptoms may prevent them from doing so. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study illustrates the need to treat difficult symptoms so that patients can maintain their employment.

Improved treatments have helped to prolong the lives of patients with metastatic cancer. Because individuals diagnosed with metastatic cancer may wish to continue to work, understanding how their illness affects their employment may help patients make adjustments.

A team led by Amye Tevaarwerk, MD, of the University of Wisconsin-Madison, analyzed the Eastern Cooperative Oncology Group's "Symptom Outcomes and Practice Patterns (SOAPP)" study to investigate which factors are associated with employment changes among patients with metastatic cancer. Among the 668 patients in the analysis, 236 (35 percent) worked full- or part-time while 302 (45 percent) stopped working due to illness. Overall, 58 percent reported some change in employment due to illness.

After comparing patients who were stably working with patients who were no longer working, the researchers found that one of the most significant factors associated with no longer working was a high burden of symptoms. Better performance status and non-Hispanic White ethnicity/race were associated with continuing to work despite a metastatic cancer diagnosis. Surprisingly, the type of cancer treatment, type of cancer, and time since diagnosis did not seem to affect employment.

"For patients with metastatic cancer, a great deal of attention is focused on the events surrounding initial diagnosis of disease and the issues surrounding the end-of-life; however, between cancer recurrence and the end-of-life, these patients are living their lives day-to-day and there are a number of unique survivorship issues during this time that have been overlooked by researchers," said Dr. Tevaarwerk. "Based on our data, we expect roughly one-third of metastatic patients will continue to try and work. Efforts to control symptoms may enable more patients to achieve this particular goal, and further research is needed to help us understand what other resources would benefit metastatic patients continuing to work."
-end-
Article: "Working after a metastatic cancer diagnosis: factors affecting employment in the metastatic setting from ECOG's Symptom Outcomes and Practice Patterns (SOAPP) study. Amye Tevaarwerk, Ju-Whei Lee, Abigail Terhaar, Mary Sesto, Mary Lou Smith, Charles Cleeland, and Michael Fisch. CANCER; Published Online: December 21, 2015 (DOI: 10.1002/cncr.29656).

URL Upon Publication: http://www.doi.wiley.com/10.1002/cncr.29656

Author Contact: Susan Lampert Smith, of the University of Wisconsin-Madison's press office, SSmith5@uwhealth.org or +1 608-890-5643.

CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology and course of human cancer. CANCER is published by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.

Wiley

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...